Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

NCT00724971 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, B-Cell

Interventions

DRUG: Inotuzumab Ozogamicin (CMC-544)
DRUG: Rituximab (Rituxan)

Sponsor

Pfizer